+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ultra-Large Volume Wearable Injectors Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • PDF Icon

    Report

  • 197 Pages
  • February 2020
  • Region: Global
  • Allied Market Research
  • ID: 5019883
The ultra large volume wearable injectors market accounted for $1,408 million in 2018, and is expected to reach $4,066 million by 2026, registering a CAGR of 14.2% from 2019 to 2026.

Ultra large volume wearable injectors are devices specially designed to stick to the body. These devices work on different mechanisms to deliver drug to the patient through subcutaneous route over an extended period of time. Furthermore, these devices have drug reservoirs that can store drugs solution of 2ml or more then 2ml. For instance, these devices function on mechanisms such as electromechanical, mechanical, and others. In addition, the electromechanical devices work with the help of electrical motor, which is responsible to build pressure for drug delivery. However, mechanical devices use osmosis to deliver the drug to the body of the patient. Furthermore, there are different benefits associated with the use of these devices. These include better patient compliance as this eliminates the need of frequent drug administration, easy ambulation as the patient is not tethered to an IV line, self-administration which lowers the frequency of healthcare professional visits, and others. In addition, these devices are used for the treatment of various chronic conditions such as cancer, diabetes, Parkinson’s diseases, and others.

The major factor that contributes toward the growth of the ultra large volume wearable injectors market include surge in prevalence of chronic disorders such as diabetes, cancer, and others. Furthermore, other factors such as benefits associated with the use of ultra large volume wearable injectors and rise in adoption of these devices across the globe fuel the growth of the market.

Moreover, surge in the demand of more advanced treatment options for chronic diseases such as diabetes contributes toward the growth of the market. In addition, increase in focus by key players toward launch of new products in the market has led to rise in collaborations within the market, which fuels the growth of the market. However, high price of ultra large volume wearable devices restrict the global ultra large volume wearable injectors market growth. In contradiction, presence of ultra large volume wearable devices in development phase, which are expected to be introduced during the forecast period is expected to provide lucrative opportunities for the players in the market.

The ultra large volume wearable injectors market is segmented on the basis of product type, application, and region to provide a detailed assessment of the market. By product type, the market is divided into electromechanical wearable injectors and others. By application, it is classified into diabetes, cancer and others. By region, the ultra large volume wearable injector market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major players operating in the market include Amgen Inc., Becton, Dickinson And Company, CeQur SA, Enable Injections, Inc., Gerresheimer AG (Sensile Medical AG), Insulet Corporation, Medtronic plc., Tandem Diabetes Care, Inc., West Pharmaceutical Services, Inc., and Ypsomed Holding AG.

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

KEY MARKET SEGMENTS

By Product Type
  • Electromechanical Wearable Injectors
  • Others

By Application
  • Diabetes
  • Cancer
  • Others

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profiled in the report
  • Amgen Inc.
  • Becton, Dickinson And Company
  • CeQur SA
  • Enable Injections, Inc.
  • Gerresheimer AG (Sensile Medical AG)
  • Insulet Corporation
  • Medtronic plc.
  • Tandem Diabetes Care, Inc.
  • West Pharmaceutical Services, Inc.,
  • Ypsomed Holding AG

LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request.)
  • E3D Elcam Drug Delivery Devices.
  • Subcuject ApS

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping ultra large volume wearable injectors industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic disorders which require the use of ultra large volume wearable injectors for treatment
3.4.1.2. Surge in adoption of ultra large volume wearable injectors across the globe
3.4.1.3. Benefits associated with the use of ultra large volume wearable injectors
3.4.2. Restraint
3.4.2.1. High cost of ultra large volume wearable injectors
3.4.3. Opportunity
3.4.3.1. Presence of products in development phase
3.4.4. Impact Analyses
CHAPTER 4: ULTRA LARGE VOLUME WEARABLE INJECTORS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Electromechanical Wearable Injector
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Others
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
CHAPTER 5: ULTRA LARGE VOLUME WEARABLE INJECTORS, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Diabetes
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: ULTRA LARGE VOLUME WEARABLE INJECTORS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. ultra large volume wearable injectors market, by product type
6.2.2.1.2. U.S. ultra large volume wearable injectors market, by application
6.2.2.2. Canada
6.2.2.2.1. Canada ultra large volume wearable injectors market, by product type
6.2.2.2.2. Canada ultra large volume wearable injectors market, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico ultra large volume wearable injectors market, by product type
6.2.2.3.2. Mexico ultra large volume wearable injectors market, by application
6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany ultra large volume wearable injectors market, by product type
6.3.2.1.2. Germany ultra large volume wearable injectors market, by application
6.3.2.2. France
6.3.2.2.1. France ultra large volume wearable injectors market, by product type
6.3.2.2.2. France ultra large volume wearable injectors market, by application
6.3.2.3. UK
6.3.2.3.1. UK ultra large volume wearable injectors market, by product type
6.3.2.3.2. UK ultra large volume wearable injectors market, by application
6.3.2.4. Italy
6.3.2.4.1. Italy ultra large volume wearable injectors market, by product type
6.3.2.4.2. Italy ultra large volume wearable injectors market, by application
6.3.2.5. Spain
6.3.2.5.1. Spain ultra large volume wearable injectors market, by product type
6.3.2.5.2. Spain ultra large volume wearable injectors market, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe ultra large volume wearable injectors market, by product type
6.3.2.6.2. Rest of Europe ultra large volume wearable injectors market, by application
6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan ultra large volume wearable injectors market, by product type
6.4.2.1.2. Japan ultra large volume wearable injectors market, by application
6.4.2.2. China
6.4.2.2.1. China ultra large volume wearable injectors market, by product type
6.4.2.2.2. China ultra large volume wearable injectors market, by application
6.4.2.3. Australia
6.4.2.3.1. Australia ultra large volume wearable injectors market, by product type
6.4.2.3.2. Australia ultra large volume wearable injectors market, by application
6.4.2.4. India
6.4.2.4.1. India ultra large volume wearable injectors market, by product type
6.4.2.4.2. India ultra large volume wearable injectors market, by application
6.4.2.5. South Korea
6.4.2.5.1. South Korea ultra large volume wearable injectors market, by product type
6.4.2.5.2. South Korea ultra large volume wearable injectors market, by application
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific ultra large volume wearable injectors market, by product type
6.4.2.6.2. Rest of Asia-Pacific ultra large volume wearable injectors market, by application
6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil ultra large volume wearable injectors market, by product type
6.5.2.1.2. Brazil ultra large volume wearable injectors market, by application
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia ultra large volume wearable injectors market, by product type
6.5.2.2.2. Saudi Arabia ultra large volume wearable injectors market, by application
6.5.2.3. South Africa
6.5.2.3.1. South Africa ultra large volume wearable injectors market, by product type
6.5.2.3.2. South Africa ultra large volume wearable injectors market, by application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA ultra large volume wearable injectors market, by product type
6.5.2.4.2. Rest of LAMEA ultra large volume wearable injectors market, by application
6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. BECTON, DICKINSON AND COMPANY
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. INSULET CORPORATION
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. TANDEM DIABETES CARE, INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. YPSOMED HOLDING AG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. ENABLE INJECTIONS, INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Product portfolio
7.5.4. Key strategic moves and developments
7.6. MEDTRONIC PLC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. AMGEN INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. GERRESHEIMER AG (SENSILE MEDICAL AG)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. WEST PHARMACEUTICAL SERVICES, INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business Performance
7.10. CEQUR SA
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Product portfolio

Executive Summary

According to the report titled 'Ultra-Large Volume Wearable Injectors Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global ultra-large volume wearable injectors market was valued at $1 billion in 2018, and is expected to reach $4 billion by 2026, registering a CAGR of 14.2% from 2019 to 2026.

Ultra large volume wearable injector is defined as the device capable of delivery of large volume of drug to the body of a patient over an extended period of time. Furthermore, these devices can deliver a drug solution of volume 2ml or more through the subcutaneous route. These are defined as wearable injectors as the devices have self-adhesive back, which can be applied to the body of the patient.

In addition, the drug delivery depends on the mechanism of the device such as electromechanical wearable injectors deliver drug with the help of electric motor that builds pressure required for drug delivery. The other type of mechanism includes the drugs delivery, which is based on osmosis mechanism. Moreover, these devices are used in the treatment of diseases such as diabetes, cancer, and others.

Surge in the prevalence of chronic disorders such as diabetes, cancer, and others is the major factor that contributes toward the growth of the ultra large volume wearable injectors market. In addition, surge in the demand for more advanced treatment options for chronic diseases such as diabetes boosts the growth of the market. In addition, increase in focus by key players toward launch of new products in the market has led to rise in collaborations with in the market which also fuels the growth of the market. Moreover, other factors such as benefits associated with the use of ultra large volume wearable injectors and rise in the adoption of these devices across the globe fuel the market growth. However, high price of ultra large volume wearable devices restrict the growth of the global ultra large volume wearable injectors market during the forecast period.

In contradiction, presence of ultra large volume wearable devices in development phase, which are expected to be introduced during the forecast period is expected to provide lucrative opportunities for the players in the market.

The ultra large volume wearable injectors market is segmented on the basis of product type, application, and region to provide a detailed assessment of the market. By product type, the market is divided into electromechanical wearable injectors and others. By application, it is classified into diabetes, cancer, and others. By region, the ultra large volume wearable injector market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, rest of Asia-Pacific and others), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

On the basis of product type, the market is divided into electromechanical wearable injector, and others. Electromechanical wearable injector acquired the major share of the ultra large volume wearable injectors market and is expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to surge in prevalence cancer and diabetes worldwide. Moreover, rise in awareness related to use of ultra large volume wearable injectors and surge in demand for advanced treatment options for chronic diseases such as diabetes fuel the growth of the market. Furthermore, presence of large number of electromechanical wearable injectors is another major factor that contributes to the growth of the market.

By application, the market is segmented into diabetes, cancer and others, research laboratories, and others. The diabetes segment occupied the largest share of the market in 2018 and is expected to maintain the lead during the forecast period.

The growth of this segment is attributable to the presence of large number of ultra large volume wearable injectors, which are used to treat diabetes. Furthermore, the cancer segment is expected to exhibit fastest growth rate during the forecast period owing to surge in wide spread prevalence of cancer across the globe.

According to Onkar Sumant, Manager, Healthcare, “The demand for ultra-large volume wearable injectors is on a rise, owing to surge in incidence of chronic diseases such as diabetes and cancer. Furthermore, rise in awareness related to use of ultra-large volume wearable injectors across the globe is another factor that fuels the growth of the market.”

KEY FINDINGS OF THE STUDY
  • By type, the electromechanical wearable injectors segment occupied more than three-fourth share of the global ultra large volume wearable injectors market in 2018.
  • By application, the cancer segment is anticipated to grow with the highest CAGR throughout the forecast period
  • By application, the diabetes segment accounted for two-third share of the market in 2018.
  • By region, Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Companies Mentioned

  • Amgen Inc.
  • Becton
  • Dickinson And Company
  • CeQur SA
  • Enable Injections Inc.
  • Gerresheimer AG (Sensile Medical AG)
  • Insulet Corporation
  • Medtronic plc.
  • Tandem Diabetes Care Inc.
  • West Pharmaceutical Services Inc.
  • Ypsomed Holding AG.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...